CN111358781A - 鞣花酸在防治新型冠状病毒感染中的应用 - Google Patents
鞣花酸在防治新型冠状病毒感染中的应用 Download PDFInfo
- Publication number
- CN111358781A CN111358781A CN202010311160.3A CN202010311160A CN111358781A CN 111358781 A CN111358781 A CN 111358781A CN 202010311160 A CN202010311160 A CN 202010311160A CN 111358781 A CN111358781 A CN 111358781A
- Authority
- CN
- China
- Prior art keywords
- compound
- ellagic acid
- infection
- preventing
- products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 title claims abstract description 26
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 title claims abstract description 14
- 229920002079 Ellagic acid Polymers 0.000 title claims abstract description 14
- 229960002852 ellagic acid Drugs 0.000 title claims abstract description 14
- 235000004132 ellagic acid Nutrition 0.000 title claims abstract description 14
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000011987 methylation Effects 0.000 claims abstract description 5
- 238000007069 methylation reaction Methods 0.000 claims abstract description 5
- 239000003607 modifier Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 239000000645 desinfectant Substances 0.000 claims description 7
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- 239000008269 hand cream Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 244000294611 Punica granatum Species 0.000 claims description 3
- 235000014360 Punica granatum Nutrition 0.000 claims description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 3
- 235000021029 blackberry Nutrition 0.000 claims description 3
- 235000021014 blueberries Nutrition 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 235000011552 Rhamnus crocea Nutrition 0.000 claims description 2
- 235000017848 Rubus fruticosus Nutrition 0.000 claims description 2
- 241000759263 Ventia crocea Species 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- -1 hand sanitizer Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 abstract description 24
- 208000015181 infectious disease Diseases 0.000 abstract description 18
- 238000012356 Product development Methods 0.000 abstract description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000021013 raspberries Nutrition 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1192—Protective face masks, e.g. for surgical use, or for use in foul atmospheres with antimicrobial agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Pest Control & Pesticides (AREA)
- General Chemical & Material Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Textile Engineering (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一类高效特异性防治新型冠状病毒感染的化合物及其应用，属于医药技术领域。该化合物有效成分包括鞣花酸、鞣花酸衍生物（包括但不限于鞣花酸甲基化产物、鞣花酸结构修饰物等类似物），有效使用浓度范围为10 ng/ml至1000 ug/ml或10 ng/g至1000 ug/g。利用该化合物进行产品开发，所开发产品用于防治新冠病毒的感染，可特异性减弱新冠病毒的侵染能力，从而防治新冠病毒的感染，降低人传人风险。
Description
技术领域
本发明属于医药技术领域，具体的说，涉及一类高效特异性防治新型冠状病毒感染的化合物及其应用。
背景技术
新型冠状病毒肺炎，简称“新冠肺炎”，是一类急性传染性疾病，由2019新型冠状病毒（2019-nCoV）感染引起。人感染了新型冠状病毒以后，其主要症状包括呼吸道症状、发热、咳嗽、气促和呼吸困难等，在较严重病例中，感染可导致肺炎、严重急性呼吸综合征、肾衰竭，甚至死亡。目前针对新型冠状病毒引起的疾病，缺乏针对病原体的有效抗病毒药物，以隔离治疗、对症支持治疗为主。同时对广大易感人群，目前的防护产品如口罩、含酒精消毒用品等均为广谱式防护，市场上尚无高效、特异性阻隔病毒传染的防护用品。因此，利用现代科学技术，开发作用明确，具有高效、特异性防治新冠病毒感染的产品符合大众需求并具有极为重要的现实意义和社会意义。
发明内容
基于现有防护用品只能进行广谱式防护，没有针对新型冠状病毒的高效、特异性防护产品的现状，本发明目的在于提供一类高效特异性防治病毒感染的化合物，特别是高效特异性防治新型冠状病毒感染的化合物，能够减弱新冠病毒的侵染能力，从而高效、特异性防治新冠病毒的感染，降低人传人风险。
为实现上述目的，本发明是通过如下技术方案实现的：
所述的一类高效特异性防治病毒感染的化合物，该化合物主要成分包括鞣花酸、鞣花酸衍生物，其中鞣花酸衍生物包括但不限于鞣花酸甲基化产物、鞣花酸结构修饰物等类似物。
进一步优选，所述的化合物由黑莓、红莓、蓝莓、石榴等水果中提取物或化学合成制备而成。
进一步优选，所述化合物有效使用浓度范围为1 -1000 ug/ml或1 -1000 ug/g。
所述的化合物在制备具有防治新冠病毒感染作用的产品中的应用。
进一步优选，所述产品包括药物、医疗设备、保健品、消杀用品或防护用品；所述药物或保健品的形式包括但不限于片剂、颗粒剂、硬胶囊、软胶囊、口服液、粉剂、合剂、丸剂、滴丸、喷雾剂、气雾剂、粉雾剂、滴眼液、牙膏、漱口水、面膜、护手霜；所述消杀用品包括但不限于肥皂、洗手液、消毒液、消毒凝胶、湿纸巾、洗衣液、口罩等。
本发明的有益效果：
本发明提供一类能够特异性靶向新型冠状病毒的化合物，该化合物有效成分包括鞣花酸、鞣花酸衍生物（包括但不限于鞣花酸甲基化产物、鞣花酸结构修饰物等类似物），有效使用浓度范围为10 ng/ml至1000 ug/ml或10 ng/g至1000 ug/g。利用该化合物进行产品开发，所开发产品用于防治新冠病毒的感染，可特异性减弱新冠病毒的侵染能力，从而防治新冠病毒的感染，降低人传人风险。
具体实施方式
为了使本发明的目的、技术方案和有益效果更加清楚，下面将对本发明的优选实施例进行详细的说明，以方便技术人员理解。
本发明为包含有一类具有高效特异性防治新冠病毒感染的化合物有效成分的药物、医疗器械、保健品或消杀用品等产品。
实例1
消毒凝胶中添加有效浓度范围内的鞣花酸，添加后的消毒凝胶在可以有效降低新冠病毒在皮肤表面的残留，进而降低感染风险。
实例2
口罩夹层中添加有效浓度范围内的鞣花酸，有效隔绝口罩外侧新冠病毒通过呼吸方式进入到呼吸系统。
实例3
护手霜中添加有效浓度范围内的化合物，添加后的护手霜涂抹在皮肤表面后，有效清除新冠病毒在手部的残留，有效清除皮肤表面的残留，进而降低感染风险。
实例4
消毒液中添加有效浓度范围内的化合物，通过喷洒的方式释放到环境中，降低环境中新冠病毒的传染能力，减小感染风险。
实例5
湿纸巾中添加有效浓度范围内的化合物，外出时通过擦拭手预防新冠病毒在手上的残留，减小感染风险。
本发明提供一类能够特异性靶向新型冠状病毒的化合物，并利用该化合物进行产品开发。该化合物的有效成分由黑莓、红莓、蓝莓、石榴等水果中提取物或化学合成制备而成，主要成分包括鞣花酸、鞣花酸衍生物（包括且不限于鞣花酸甲基化产物、鞣花酸结构修饰物等类似物）。
产品中有效成分在分子互作研究中发现，其与新型冠状病毒表面免疫原（配体）特异性结合，且在该化合物有效浓度范围内降低配体与新冠病毒的受体（ACE2）的结合响应值；该研究结果提示产品中有效成分可特异性减弱新冠病毒的侵染能力，从而防治新冠病毒的感染，降低人传人风险。
最后说明的是，以上优选实施例仅用于说明本发明的技术方案而非限制，尽管通过上述优选实施例已经对本发明进行了详细的描述，但本领域技术人员应当理解，可以在形式上和细节上对其作出各种各样的改变，而不偏离本发明权利要求书所限定的范围。
Claims (5)
1.一类高效特异性防治病毒感染的化合物，其特征在于：所述化合物主要成分包括鞣花酸、鞣花酸衍生物，其中鞣花酸衍生物包括但不限于鞣花酸甲基化产物、鞣花酸结构修饰物等类似物。
2.根据权利要求1所述的化合物，其特征在于：所述的化合物由黑莓、红莓、蓝莓、石榴等水果中提取物或化学合成制备而成。
3.根据权利要求1所述的化合物，其特征在于：所述化合物有效使用浓度范围为1 -1000 ug/ml或1 -1000 ug/g。
4.权利要求1 -3任一项所述的化合物在制备具有防治新冠病毒感染作用的产品中的应用。
5.根据权利要求4所述的化合物在制备具有防治新冠病毒感染作用的产品中的应用，其特征在于：所述产品包括药物、医疗设备、保健品、消杀用品或防护用品；所述药物或保健品的形式包括但不限于片剂、颗粒剂、硬胶囊、软胶囊、口服液、粉剂、合剂、丸剂、滴丸、喷雾剂、气雾剂、粉雾剂、滴眼液、牙膏、漱口水、面膜、护手霜；所述消杀用品包括但不限于肥皂、洗手液、消毒液、消毒凝胶、湿纸巾、洗衣液、口罩。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010311160.3A CN111358781A (zh) | 2020-04-20 | 2020-04-20 | 鞣花酸在防治新型冠状病毒感染中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010311160.3A CN111358781A (zh) | 2020-04-20 | 2020-04-20 | 鞣花酸在防治新型冠状病毒感染中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111358781A true CN111358781A (zh) | 2020-07-03 |
Family
ID=71201650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010311160.3A Pending CN111358781A (zh) | 2020-04-20 | 2020-04-20 | 鞣花酸在防治新型冠状病毒感染中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111358781A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112716822A (zh) * | 2021-02-03 | 2021-04-30 | 深圳市南门科技有限公司 | 一种抗新冠病毒的消毒液及其制备方法 |
| CN112772913A (zh) * | 2021-01-25 | 2021-05-11 | 昆明生物制造研究院有限公司 | 一种西洋参玫瑰酵素及其制备方法 |
| CN112868955A (zh) * | 2021-01-25 | 2021-06-01 | 昆明生物制造研究院有限公司 | 一种人参金银花复合发酵饮品及其制备方法 |
| CN113995748A (zh) * | 2021-11-17 | 2022-02-01 | 武汉轻工大学 | 鞣花酸在制备治疗或预防猪病毒性腹泻药物或饲料添加剂中的应用 |
| IT202000018949A1 (it) * | 2020-08-03 | 2022-02-03 | Arterra Bioscience S P A | Estratto derivato da bucce di punica granatum per la prevenzione e il trattamento di infezioni virali |
| WO2022166933A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海科技大学 | 化合物在抗冠状病毒中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090042793A1 (en) * | 2005-09-21 | 2009-02-12 | Jan Balzarini | Novel Antiviral Therapies |
| CN102485231A (zh) * | 2010-12-03 | 2012-06-06 | 南京中医药大学 | 假奓包叶提取物及其制备方法和用途 |
| CN102670588A (zh) * | 2012-05-04 | 2012-09-19 | 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 | 鞣花酸用于制备抗病毒药物的应用 |
| WO2021212269A1 (zh) * | 2020-04-20 | 2021-10-28 | 云南农业大学 | 鞣花酸在防治新型冠状病毒感染中的应用 |
-
2020
- 2020-04-20 CN CN202010311160.3A patent/CN111358781A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090042793A1 (en) * | 2005-09-21 | 2009-02-12 | Jan Balzarini | Novel Antiviral Therapies |
| CN102485231A (zh) * | 2010-12-03 | 2012-06-06 | 南京中医药大学 | 假奓包叶提取物及其制备方法和用途 |
| CN102670588A (zh) * | 2012-05-04 | 2012-09-19 | 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 | 鞣花酸用于制备抗病毒药物的应用 |
| WO2021212269A1 (zh) * | 2020-04-20 | 2021-10-28 | 云南农业大学 | 鞣花酸在防治新型冠状病毒感染中的应用 |
Non-Patent Citations (3)
| Title |
|---|
| BABATUNDE OSO，等: "Molecular Docking and ADMET Prediction of Natural Compounds towards SARS Spike Glycoprotein-Human Angiotensin Converting Enzyme 2 and SARS-CoV-2 Main Protease", 《MENDELEY DATA》 * |
| 苑兆和，等: "石榴植物化学研究进展", 《落叶果树》 * |
| 谢传奇，等: "表没食子儿茶素没食子酸酯( EGCG)自然氧化产物的分析", 《西南农业学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000018949A1 (it) * | 2020-08-03 | 2022-02-03 | Arterra Bioscience S P A | Estratto derivato da bucce di punica granatum per la prevenzione e il trattamento di infezioni virali |
| CN112772913A (zh) * | 2021-01-25 | 2021-05-11 | 昆明生物制造研究院有限公司 | 一种西洋参玫瑰酵素及其制备方法 |
| CN112868955A (zh) * | 2021-01-25 | 2021-06-01 | 昆明生物制造研究院有限公司 | 一种人参金银花复合发酵饮品及其制备方法 |
| CN112716822A (zh) * | 2021-02-03 | 2021-04-30 | 深圳市南门科技有限公司 | 一种抗新冠病毒的消毒液及其制备方法 |
| WO2022166933A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海科技大学 | 化合物在抗冠状病毒中的应用 |
| CN113995748A (zh) * | 2021-11-17 | 2022-02-01 | 武汉轻工大学 | 鞣花酸在制备治疗或预防猪病毒性腹泻药物或饲料添加剂中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111358781A (zh) | 鞣花酸在防治新型冠状病毒感染中的应用 | |
| CN111387194A (zh) | 一类高效特异性防治新型冠状病毒感染的化合物及其应用 | |
| US4767788A (en) | Glutaric acid virucidal processes and compositions | |
| EA018138B1 (ru) | Применение йота-каррагенана в качестве противовирусного ингредиента | |
| WO1998056761A3 (en) | Benzimidazole derivatives | |
| JP5470047B2 (ja) | 抗ウイルス組成物及び使用方法 | |
| DK169437B1 (da) | Chloreret uracilnucleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et lægemiddel mod en adenovirusinfektion, farmaceutiske præparater indeholdende forbindelsen samt fremgangsmåde ti l fremstilling af forbindelsen | |
| CA2545157A1 (en) | Disinfecting composition and methods of making and using same | |
| KR20110074513A (ko) | 피부 감염의 국소 치료법 | |
| EP0198061A1 (en) | Use of compositions comprising sulfosuccinates for the manufacture of a medicament for preventing or treating viral infections | |
| JP2017522330A (ja) | ポビドンヨードを使用した感冒の治療および予防 | |
| CN108371191A (zh) | 一种空气消毒液及其制备方法和应用 | |
| CA2439413C (en) | Virucidal compositions | |
| CN111358779A (zh) | 苦杏碱醇a在防治新型冠状病毒感染中的应用 | |
| NZ324380A (en) | Therapeutic benzimidazole compounds and their use in treatment of virus infections | |
| CN112043701A (zh) | 长链季铵盐类化合物的医药用途 | |
| WO2021212269A1 (zh) | 鞣花酸在防治新型冠状病毒感染中的应用 | |
| WO2021212270A1 (zh) | 苦杏碱醇a在防治新型冠状病毒感染中的应用 | |
| CA1172170A (en) | Antiviral alpha, alpha-dialkyl adamantylethylamines | |
| US20060287364A1 (en) | Methods of prevention of infection with HIV/AIDS, venereal disease and influenza | |
| JPH06505733A (ja) | ミクロスポリディア症の治療におけるベンゾイミダゾール駆虫薬の使用 | |
| US11266145B2 (en) | Compositions comprising protocatechuic acid and methods of use | |
| BRPI0408441A (pt) | 2-(butil-1-sulfonilamino)-n-[1(r)-(6-metóxi-piridin-3-il)-p ropil]-benzamida, seu emprego como medicamento, assim como preparados farmacêuticos contendo-os | |
| RU2232711C1 (ru) | Способ получения дифторида ксенона, способ его очистки от взрывоопасных примесей и его использование | |
| Mottaghi | Prophylactic effects of mouthwashes on covid-19 and its family viruses: A systematic review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200703 |